Generic Medicine Info
Indications and Dosage
Prophylaxis of migraine
Adult: In patients who have at least 4 migraine days per month: 70 mg once every 4 weeks, may increase to 140 mg every 4 weeks if necessary. Consider discontinuing treatment if there is no response after 3 months.
Special Precautions
Patient with CV or cerebrovascular diseases. Pregnancy and lactation.
Adverse Reactions
Significant: Constipation, hypersensitivity reactions (e.g. rash, angioedema, anaphylaxis).
Injury, poisoning and procedural complications: Injection site reactions (e.g. pain, erythema).
Musculoskeletal and connective tissue disorders: Muscle cramps or spasm.
Monitoring Parameters
Monitor the number of monthly migraine days and the treatment benefit within 3 months after initiation.
Mechanism of Action: Erenumab is a recombinant human monoclonal antibody which binds to and inhibits the activity of calcitonin gene-related peptide (CGRP), a peptide involved in the pathophysiology of migraine.
Absorption: Bioavailability: 82%. Time to peak plasma concentration: Approx 6 days.
Distribution: Crosses placenta.
Metabolism: Metabolised via nonspecific, nonsaturable proteolytic pathways.
Excretion: Elimination half-life: 28 days.
Store between 2-8°C. Do not freeze or shake. Protect from light.
MIMS Class
Antimigraine Preparations
ATC Classification
N02CD01 - erenumab ; Belongs to the class of calcitonin gene-related peptide (CGRP) antagonists preparations. Used to relieve migraine.
Aimovig Injection, Solution (Amgen Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 07/04/2020.

Anon. Erenumab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 07/04/2020.

Anon. Erenumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/04/2020.

Buckingham R (ed). Erenumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/04/2020.

Joint Formulary Committee. Erenumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 07/04/2020.

Disclaimer: This information is independently developed by MIMS based on Erenumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in